Loading...
NPI 1588004410 · Williston, ND · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Medscan Laboratory Inc is a clinical medical laboratory provider located in Williston, North Dakota. This profile covers 122 Medicare and 149 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Medscan Laboratory Inc |
| Address | 1502 13th Ave W Ste 201 |
| City | Williston |
| State | ND |
| ZIP | 58801 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 25, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $14.8M |
| Medicare | $7.2M |
MEDSCAN LABORATORY INC is a clinical medical laboratory with an NPI enumerated since 2013-06-25 (~13 years ago), indicating more than a decade of billing history to analyze and an established presence in lab services in Williston, ND.
Medicaid is the larger payer relationship by revenue for this provider: total Medicaid revenue is $14.8M versus total Medicare revenue of $7.2M, making Medicaid roughly double Medicare in lifetime revenue and indicating the business relies more heavily on state-payer volume and contracts.
Revenue concentration is high for both payers. Precomputed shares show the top three Medicare codes account for 54.8% of Medicare revenue while the top three Medicaid codes account for 70.5% of Medicaid revenue, signaling that a small group of tests—primarily definitive drug testing and high-volume infectious disease panels—drive most reimbursement.
The provider’s Medicare billing is heavily dominated by G0483, which generated $2.7M (42.3% of Medicare revenue) and ranks #7 of 1063 nationally (99th percentile) — characterized in the source as an "extreme outlier" and indicating MEDSCAN operates at a scale for definitive multi-class drug testing far above most national peers.
On Medicaid, G0483 likewise dominates with $7.2M (51.8% of Medicaid revenue) and is ranked #1 of 3 in-state (100th percentile). This leadership is mirrored across other drug-testing codes (G0482, G0480, G0481, 80307), where MEDSCAN repeatedly ranks first in-state and is described as an extreme or notable outlier, indicating the lab is the primary in-state provider for definitive and presumptive drug testing services.
The provider also reported very high state-volume for COVID molecular testing codes (U0003, U0005) on Medicaid — each contributing materially to Medicaid revenue ($1.2M for U0003 and $213.7K for U0005) and ranking #1 in-state (100th percentile). This pattern suggests MEDSCAN scaled molecular testing capacity during the pandemic and that infectious disease testing is a meaningful secondary service line.
Beyond drug testing and COVID-era molecular testing, MEDSCAN bills a broad menu of routine and specialty chemistry and hormonal assays (e.g., 82306 vitamin D, 83970 PTH, 84443 TSH, 83698 Lp-PLA2) across Medicare and Medicaid, indicating a full-service clinical lab footprint that supports both common panels and niche endocrine/cardiovascular tests.
Competitive standing differs by payer and code: nationally for Medicare MEDSCAN is an extreme outlier on several codes (G0483 and 84270 among them) and ranks in the top percentiles on many others, reflecting unusually high national-scale volume in specific definitive-testing services; in-state for Medicaid the firm is frequently the top-ranked provider for the highest-revenue codes, showing state-level dominance in drug testing and COVID testing.
The billing profile implies a business model centered on high-volume definitive drug panels and related specimen collection (P9603 appears on Medicare with large claim counts), complemented by pandemic PCR throughput and a suite of routine chemistry and endocrine assays — a mix that supports stable Medicaid-driven revenue, concentrated around a few high-volume codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
122 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 11,200 | $240 | $2.7M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 7,460 | $60 | $454.9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,100 | $110 | $347.4K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 7,640 | $30 | $221.5K |
| 83970 | Parathyroid hormone test measures the level of PTH in the blood. This test is done to ascertain the level of calcium and evaluate the parathyroid function. | 4,990 | $40 | $199.5K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,000 | $200 | $194.6K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 11,720 | $20 | $187.5K |
| 83698 | The lab analyst measures the amount of lipoprotein associated phospholipase A2, called Lp PLA2, in the patient specimen. | 3,620 | $50 | $162.7K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 159,380 | $1 | $159.4K |
| 82607 | The lab analyst performs a test to measure the amount of vitamin B12 in a patient specimen, typically in patient blood. | 10,200 | $20 | $152.9K |
Showing 1–10 of 122
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 122 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
122 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0483 | 1 | 10 | 5,650 | $240 | $1.4M |
| P9603 | 1 | 10 | 159,380 | $1 | $173.2K |
| 83698 | 1 | 10 | 3,620 | $50 | $164.1K |
| 82172 | 1 | 10 | 6,360 | $20 | $131.4K |
| 84305 | 1 | 10 | 4,800 | $20 | $100.1K |
| 83520 | 1 | 10 | 4,260 | $20 | $72K |
| 84270 | 1 | 10 | 2,990 | $20 | $63.7K |
| G0480 | 1 | 10 | 60 | $110 | $63.2K |
| 83970 | 1 | 10 | 450 | $40 | $54.6K |
| G0482 | 1 | 10 | 70 | $190 | $41.8K |
Showing 1–10 of 122
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
149 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 72,090 | $100 | $7.2M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 25,980 | $50 | $1.4M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 47,920 | $30 | $1.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 23,810 | $50 | $1.2M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12,640 | $70 | $834.3K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 11,490 | $60 | $712.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 16,440 | $10 | $213.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4,200 | $50 | $193K |
| 87632 | The lab analyst performs a test to identify a respiratory virus using an amplified nucleic acid probe technique. He may also use the multiplex reverse transcription technique. The provider does this… | 1,580 | $90 | $143.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 5,780 | $20 | $92.5K |
Showing 1–10 of 149
How this provider's Medicaid billing volume and revenue compare to other North Dakota providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. North Dakota median
149 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 850 | $100 | $2.4M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 25,980 | $50 | $1.3M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 160 | $60 | $241.3K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 2 | 10 | 790 | $290 | $227.9K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 10 | 160 | $60 | $172.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 60 | $70 | $144.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1 | 20 | 920 | $30 | $111.2K |
| 86003 | The lab analyst performs the technical lab test to analyze a specimen such as serum for allergen–specific immunoglobulin E (IgE), using a crude allergen extract. The test result is quantitative or… | 2 | 10 | 580 | $30 | $84.1K |
| 87632 | The lab analyst performs a test to identify a respiratory virus using an amplified nucleic acid probe technique. He may also use the multiplex reverse transcription technique. The provider does this… | 1 | 10 | 800 | $90 | $72.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1 | 10 | 840 | $50 | $68.6K |
Showing 1–10 of 149
Other providers in the same ZIP code as Medscan Laboratory Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Opportunity Foundation Inc | ND | Developmentally Disabled Services Day Training Agency | $0 | $26.3M |
| Mercy Medical Center | ND | Critical Access Hospital | $0 | $4M |
| City Of Williston | ND | Land Ambulance | $398.3K | $2M |
| Opportunity Foundation Inc | ND | Early Intervention Provider Agency | $0 | $1.8M |
| Mark Raymond | ND | Ophthalmology Physician | $1.7M | $0 |
| Mercy Medical Center | ND | Clinic/Center | $0 | $1.3M |
| Summit Counseling Inc | ND | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $1.2M |
| Northwest Behavioral Health Clinic | ND | Adult Mental Health Clinic/Center | $0 | $872.7K |
| Nathan Smith | ND | Pediatric Dentistry | $0 | $712.5K |
| Ideal Option, PLLC | ND | Clinic/Center | $0 | $690.9K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.